Amphastar Pharmaceuticals (AMPH) Gross Margin (2013 - 2026)

Amphastar Pharmaceuticals' Gross Margin history runs 14 years deep, the most recent figure standing at 41.08% for Q1 2026.

• In Q1 2026, Gross Margin fell 891.0% year-over-year to 41.08%; the TTM figure through Mar 2026 stood at 47.34% (down 316.0% YoY), while the FY2025 annual figure was 49.46%, down 162.0% from the prior year.
• Gross Margin was 41.08% for Q1 2026 at Amphastar Pharmaceuticals, down from 46.79% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 60.04% in Q3 2023 to a low of 41.08% in Q1 2026.
• Historically, Gross Margin has averaged 50.53% across 5 years, with a median of 51.31% in 2022.
• The sharpest annual moves came in 2023 and 2026: Gross Margin jumped 1133 bps in 2023, then slumped 891 bps in 2026.
• A 5-year view of Gross Margin shows it stood at 52.71% in 2022, then grew by 2 bps to 53.98% in 2023, then fell by 14 bps to 46.45% in 2024, then climbed by 1 bps to 46.79% in 2025, then fell by 12 bps to 41.08% in 2026.
• The last three Gross Margin figures came in at 41.08% (Q1 2026), 46.79% (Q4 2025), and 51.42% (Q3 2025), per Business Quant data.